Abbott ABT announced
today that it will collaborate with Merck to evaluate the use of a FISH
(fluorescence in situ hybridization)-based companion diagnostic test to aid in
the development of a Merck investigational cancer therapy. FISH-based
companion diagnostic tests are designed to identify specific DNA sequences to
help guide physicians in determining which patients are more or less likely to
benefit from a particular therapy.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in